Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1626 1629
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18845718 | NOVEL TAFAMIDIS SYNTHESIS METHOD | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18240392 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 19341379 | LOW-SORBING GLYBURIDE FORMULATION AND METHODS | Final Rejection | REMEDY PHARMACEUTICALS, INC. |
| 18735506 | FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | Non-Final OA | Northwestern University |
| 18250798 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Non-Final OA | Katholieke Universiteit Leuven |
| 18850466 | TYK2 INHIBITORS AND USES THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18696960 | PIKFYVE KINASE INHIBITOR | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18516710 | SPIRO COMPOUND AND USE THEREOF | Non-Final OA | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy